Program

Cancer Immunology Program

The mission of the Cancer Immunology Program is to identify mechanisms that regulate the anti-tumor immune response and translate this information into efficacious immunotherapies for cancer patients.

Recent, High-Impact Publications

  • Cross-species single-cell atlas of the striatum defines cell-type and subregion disease vulnerabilities.

    Linville RM, James BT, Galani K, Ho LL, Shin JH, Oliver E, Fass SB, Cameron JC, Fitzwalter BE, Bock R, Murray EM, Louçã M, Oke O, Wang C, Engelberg-Cook E, DeTure M, Farrell V, Pineda SS, Sathitloetsakun S, Liang X, Madras B, Dickson DW, Mash DC, Turecki G, Wheeler VC, Alvarez VA, Gabuzda D, Kellis M, Heiman M

  • Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4.

    Chu C, Zheng S, Mitchell N, Li Z, Zhang X, Wu X, Zhang T, Dang F, Michowski W, Kolodziejczyk A, Xu ML, Kotowski KW, Yang Z, Martinez-Alonso D, Paulo J, Sheng J, Kirby JA, Groezinger F, Zhou Y, He M, Ito Y, Gulvady AC, Cole MI, Foidart P, Nishida J, Ning X, Sharma S, Suski JM, Fassl A, Zhou Y, Geng Y, Wei W, Gygi SP, Polyak K, Wucherpfennig KW, Sicinski P

    Molecular cell 2026.PubMed(opens in new window)
  • TCR origin and specificity to environmental or self-antigens on distinct antigen-presenting cells determine peripheral Treg cell differentiation.

    Chi X, Wang CH, Parisotto YF, Nyberg WA, Cabric V, Gelineau A, Cao Y, Owen DL, Ambjörnsson J, Mathis D, Eyquem J, Brown CC, Benoist C

  • Non-genotoxic transplantation and in vivo selection through epitope editing.

    Casirati G, Cosentino A, Freschi M, Zeng J, Mucci A, Levesque S, Neri N, Drago E, Carzaniga V, Romano F, Katta V, Matsubara A, Li Y, Mahmoud MS, Chávez-Navarro M, Brendel C, Manis JP, Tsai S, Pellin D, Bauer D, Genovese P

  • Macrophage-derived itaconate is a negative regulator of adipose tissue thermogenesis.

    Tang J, Pernes G, Nakagaki B, Tran N, Bokor L, Prenen F, Yi M, Robertson AE, Cronin R, Sarmini M, Pierscianowski J, Roberts V, Ryback BA, Novina CD, Auclair K, Xiao H, Mills EL

    Nature Metabolism 2026.PubMed(opens in new window)
  • Genomic correlates of clinical CAR T cell activity.

    Leick MB, Sun B, Birocchi F, Gallagher KME, Bratt A, Han S, Martin G, Silva HJ, Larson RC, Chinsky TM, Chu H, Reilly CR, Kann MC, Choi BD, Camp S, Gillani R, Phillips M, Kienka T, Bailey SR, Graham CE, Jan M, Moore NS, Horick N, Budka J, Filosto S, Williams CM, Hosseini Rad A, Shen RR, Van Allen E, AlDubayan S, Maus MV

    Science Immunology 2026; 11(121):eaef4134.PubMed(opens in new window)
  • The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity.

    Zhang X, Xirenayi S, Zhao Y, Wang W, Han Y, Sobral M, Kang S, Zhang C, Barlow GL, Pyrdol J, Cho JW, Huang K, Ning X, Hemberg M, Yuan GC, Van Allen EM, Mooney DJ, Wucherpfennig KW

    Science (New York, N.Y.) 2026; 393(6807):eaea1200.PubMed(opens in new window)
  • Inflammatory cytokines induce new cancer dependencies.

    Cheruiyot CK, Kim SY, Dubrot J, Lane-Reticker SK, Miranda A, Kammula AV, Perera JJ, Du PP, Chuong CL, Fetterman RA, Knudsen NH, Jiang A, Suermondt JSMT, Pass LF, Fu C, Wu MJ, Shi L, Anderson S, Muscato AJ, Avila OI, Kohnle IC, Kessler EA, Pope HW, Noel SG, Olander KE, Chung J, Colvin KJ, Bardeesy N, Yates KB, Manguso RT

    Nature genetics 2026; 58(6):1353-1367.PubMed(opens in new window)
  • Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

    Ghannam JY, Bryan J, Weiss J, Kovarsky D, Merrell D, Messer C, Schlueter-Kuck K, Fell GG, Lim-Fat MJ, Youssef G, Rahman R, Qin L, Young GS, Janes JT, Van Orden M, Pfaff KL, Gans A, Lin ES, Huang RY, Danysh BP, Parida L, Li S, Wen PY, Chiocca EA, Neuberg D, Ligon KL, Tirosh I, Reardon DA, Getz G, Wu CJ

    Nature Cancer 2026; 7(6):964-982.PubMed(opens in new window)
  • Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

    Sperling AS, Derman BA, Nikiforow S, Alonso A, Ikegawa S, Orwitz N, Quinn DS, Pearson D, Bu D, Milanez-Almeida P, Mataraza J, Nadeem O, Liegel J, D'Souza A, Charles A, Credi M, Ritz J, Jakubowiak AJ, De Vita S, Munshi NC

    Science Translational Medicine 2026; 18(851):eadx1799.PubMed(opens in new window)
  • Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

    Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; JCO2502027.PubMed(opens in new window)
  • Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

    Sweis RF, Long GV, Daud A, Stemmer SM, Jimeno A, Perets R, Kummar S, Patel MR, Khattak A, Abadier M, Van L, Guo R, Do KT, Sullivan RJ

    Clinical cancer research : an official journal of the American Association for Cancer Research 2026.PubMed(opens in new window)

Cancer Immunology Program Members

Members